A modified analysis of the NUGC-3 tumor samples showed that PC14586 administration in vivo led to changes in the expression of immune and inflammatory signaling–associated genes and gene sets (TNFSF9, CSF2, IL1A, GDF15, and TNFA signaling and inflammatory response; Supplementary Fig. S6D–S6F; Supplementary File S16). This evidence concerns the gene TNFSF9 and neoplasm.